Biosimilar Interchangeability(Interchangeability)
A higher regulatory designation than biosimilarity, requiring demonstration that a biosimilar can be substituted for its reference product without intervention from the prescribing physician.
Usage Examples
- FDA granted interchangeable designation based on 3-cycle switching study demonstrating equivalent efficacy and no immunogenicity increase.
- State pharmacy substitution laws were updated to recognize the FDA-designated interchangeable biosimilar.
What is Interchangeability?
Interchangeability is a regulatory designation unique to biologics under the BPCIA: a biosimilar designated interchangeable by FDA can be substituted for its reference product at the pharmacy level without prescriber intervention, subject to state pharmacy substitution laws. The standard goes beyond biosimilarity: the sponsor must demonstrate that the biosimilar can be expected to produce the same clinical result as the reference product in any given patient, and for products administered multiple times, that switching does not increase safety or efficacy risks.
Interchangeability typically requires switching studies: randomized switching designs comparing switched-therapy groups against single-therapy groups across multiple clinical cycles, measuring efficacy stability, safety, and immunogenicity. The evidence bar is substantially higher than biosimilarity approval, and not all biosimilars pursue interchangeability. Interchangeability enables pharmacy-level substitution, increasing commercial competitiveness with the reference product and with non-interchangeable biosimilars.
Regulatory Context
This term appears most often in submission & approval workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside PHSA SECTION 351K, BPCIA.
When This Matters
- FDA granted interchangeable designation based on 3-cycle switching study demonstrating equivalent efficacy and no immunogenicity increase.
- State pharmacy substitution laws were updated to recognize the FDA-designated interchangeable biosimilar.
Common Mistakes
- Treating submission readiness as a formatting-only check without lifecycle validation.
- Using outdated guidance references across modules and summaries.
- Missing cross-functional review between RA, CMC, and quality before submission.
Related Regulations
Frequently Asked Questions
Biosimilarity: high similarity to reference product with no clinically meaningful differences. Interchangeability: biosimilar can be substituted for reference product at pharmacy level without prescriber intervention — a higher bar requiring switching study evidence. All interchangeable biosimilars are biosimilars; not all biosimilars are interchangeable.
The biosimilarity data package plus switching studies demonstrating that alternating between the biosimilar and reference product in multiple cycles doesn't diminish safety or efficacy compared to continuous reference product use. FDA 2019 guidance describes acceptable switching study designs.
Only interchangeable biosimilars enable automatic pharmacy substitution, and only where state law permits. Non-interchangeable biosimilars can be prescribed as alternatives to the reference product but require a prescriber to specifically choose the biosimilar.
Related Terms
Related Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
Track ICH quality guidelines automatically and get alerts when changes impact your products
Related Regulatory Intelligence
Related Actions
Sources & References
